Category: 101691-65-0

The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.101691-65-0, Name is (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate, molecular formula is C13H18O4S. In a Patent£¬once mentioned of 101691-65-0, Quality Control of: (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate

SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt’s Disease.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Quality Control of: (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate, you can also check out more blogs about101691-65-0

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

101691-65-0, Name is (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate, molecular formula is C13H18O4S, belongs to Tetrahydropyrans compound, is a common compound. In a patnet, once mentioned the new application about 101691-65-0, Quality Control of: (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate

FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF

Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3Kdelta, and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Quality Control of: (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate. In my other articles, you can also check out more blogs about 101691-65-0

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

A mixture of methyl 6-(5′-bromo-2′-hydroxy-2-biphenylyl)-2-pyridinecarboxylate (200mg, 0.52mmol), tetrahydro-2H-pyran-4-ylmethyl-4-methylbenzene sulphonate (430mg, 1.5mmol) and potassium cabonate (200mg) in dimethylformamide (4ml) was heated to reflux for 3 hours under nitrogen. The reaction mixture was then filtered through celite, washed with ethyl acetate (10mls) and evaporated to an oil which was flash chromatographed eluting with diethyl ether/isohexane (1/5). The product was dissolved in methanol (10ml), treated with 2N sodium hydroxide (2ml) and heated at 70C for 15min. The solution was evaporated and partitioned between water and ethyl acetate. After drying with anhydrous sodium sulphate the ethyl acetate solution was evaporated to give the title compound (130mg). LC/MS [M+H] 470.3, 471.4, Rt=3.65min., 101691-65-0

As the paragraph descriping shows that 101691-65-0 is playing an increasingly important role.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2005/108369; (2005); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

101691-65-0, (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step B: 1 -(Tetrahvdropyran-4-yl)methyl-7-chloro-1 /-/-indole-3-carboxylic acid To a solution of 7-chloro-1 /-/-indole-3-carboxylic acid (7.5 g, 38.0 mmol) in di- methylformamide (100 ml) at 10 C under nitrogen was added sodium hydride (60% dispersion in mineral oil, 3.1 g, 76.0 mmol) portionwise over 10 mins, maintaining the temperature below 15 C. The cooling bath was removed and the suspension stirred for 90 mins. Toluene-4-sulfonic acid tetrahydopyran-4-ylmethylester (14.6 g, 53.0 mmol) was added. The mixture was heated at 50 C with stirring for 6 h. Dimethylformamide was removed by evaporation and the residue was dissolved in water (500 ml). The emulsion was washed with dichloromethane (2 x 100 ml). The aqueous phase was acidified to pH 1 using 5 M hydrochloric acid and the precipitate filtered off, washed with water to neutrality and dried to afford 1-(tetrahydropyran-4- yl)methyl-7-chloro-1 /-/-indole-3-carboxylic acid (15.0 g, 51.0 mmol) as a white solid.

101691-65-0, As the paragraph descriping shows that 101691-65-0 is playing an increasingly important role.

Reference£º
Patent; AKZO NOBEL N.V.; WO2007/23143; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

To DMF (1.5 ml) was added NaH (60% in mineral oil, 46.1 mg, 1.152 mmol) and then 5-bromo-2-fluoropyridin-3 -amine (200 mg, 1.047 mmol). The reaction mixture was stirred at room temperature for 15 minutes. Then (tetrahy dro-2H-pyran-4-yl)methyl 4- methylbenzenesulfonate (283 mg, 1.047 mmol) was added and stirred at 40 C for 40 hours. The reaction was cooled to room temperature and 100 ml of ethyl acetate was added. The resulting mixture was washed with saturated sodium bicarbonate (2x), water (2x), brine, dried sodium sulfate, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (40g column eluting with 0-40% ethyl acetate in heptane). The desired fractions were concentrated to yield 104 mg of the title compound as free base. LCMS (m/z): 288.9/290.9 (MH+), retention time = 0.88 min., 101691-65-0

Big data shows that 101691-65-0 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; ANTONIOS-MCCREA, William, R.; BARSANTI, Paul, A.; HU, Cheng; JIN, Xianming; MARTIN, Eric, J.; PAN, Yue; PFISTER, Keith, B.; SENDZIK, Martin; SUTTON, James; WAN, Lifeng; WO2012/66070; (2012); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

101691-65-0, (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 3: Synthesis of Thioacetic acid S-(tetrahydro-pyran-4-ylmethyl) ester Prepared as described by adaptation of the following literature reference:Watson, R.J. et al. Tetrahedron Lett. 2002, 43, 683-685. To a solution of 224 g (0.83 mol) of toluene-4- sulfonic acid tetrahydro-pyran-4-ylmethyl ester in methyl isobutylketone (1.6 L) are added 189 g (1.66 mol) of potassium thioacetate. The beige suspension is stirred at 70 C for 4.5 h. The reaction mixture is cooled to room temperature and water (1.8 L) is added. The organic layer is washed with 10% aqueous K2CO3 solution (1.8 L) and water (1 L). The organic layer is filtered through celite (20 g), activated charcoal (20 g) and Na2S04 (20 g) and the filtrate is concentrated under reduced pressure. The residual oil is azeotroped with methylcyclohexane (200 mL) and n-heptanes (250 mL) to afford 138 g of thioacetic acid S-(tetrahydro-pyran-4-ylmethyl) ester as a yellow-orange oil (CAUTION: Stench.). Yield: 96%; ES-MS: m/z 175 [M+H]; 1H NMR (400 MHz,CHLOROFORM-d) delta ppm 1.23 – 1.40 (2 H, m), 1.59 – 1.78 (3 H, m), 2.33 (3 H, d, 7=4.16 Hz), 2.82 (2 H, dd, 7=6.24, 3.79 Hz), 3.27- 3.39 (2 H, m), 3.88 – 4.02 (2 H, m)

101691-65-0, As the paragraph descriping shows that 101691-65-0 is playing an increasingly important role.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BARTOLOZZI, Alessandra; BERRY, Angela; RIETHER, Doris; ERMANN, Monika; JENKINS, James Edward; MUSHI, Innocent; WO2011/88015; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

Example 203B 5-methyl-3-((tetrahydro-2H-pyran-4-yl)methyl)thiazol-2(3H)-imine A mixture of Example 203A (1.9 g, 7.0 mmol), 2-amino-5-methylthiazole (0.80 g, 7.0 mmol) and tetrabutylammonium iodide (1.3 g, 3.5 mmol) in 3 mL of N,N-dimethylformamide was warmed to 85 C. and was allowed to stir for 24 hours. The mixture was diluted with 10 mL of CH2Cl2, washed with 10% aqueous NaHCO3, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Purification via column chromatography (SiO2, 10% methanol in ethyl acetate then 9:1:0.1 CH2Cl2:methanol:NH4OH) afforded the title compound. MS (DCI/NH3) m/z 213 (M+H)+.

101691-65-0, The synthetic route of 101691-65-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Florjancic, Alan S.; Dart, Michael J.; Ryther, Keith B.; Perez-Medrano, Arturo; Carroll, William A.; Patel, Meena V.; Tietje, Karin Rosemarie; Li, Tongmei; Kolasa, Teodozyj; Gallagher, Megan E.; Peddi, Sridhar; Frost, Jennifer M.; Nelson, Derek W.; US2008/58335; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

101691-65-0, (Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of the protected pyrrole 15 (6.0 g, 22.8 mmol) and ammonium chloride (390 mg, 7.3 mmol) in methanol (15 mL) was added magnesium powder (4.4 g, 180 mmol) and the mixture was sonicated for 1 hour. The reaction mixture was slowly quenched with saturated aqueous ammonium chloride (200 mL) and extracted with diethyl ether (3 x 50 mL), dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The crude pyrrole was used immediately without further purification or characterisation. To a solution of the pyrrole (2.3 g, 18.7 mmol), (tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate (6.1g, 22.4 mmol) and tetrabutylammonium bromide (603 mg, 1.9 mmol) in N,N-dimethylformamide (100 mL) at 0 C was added sodium hydride (60% dispersion in mineral oil, 972 mg, 24.3 mmol) and the mixture was immediately warmed to 50 C and stirred for 16 hours. The mixture was cooled to 0 C, quenched with saturated aqueous ammonium chloride (30 mL), diluted with water (200 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with water (3 x 100 mL) and aqueous lithium chloride (1 M, 2 x 50 mL), dried over anhydrous magnesium sulfate and concentrated. The crude product was purified by flash column chromatography using ethyl acetate, hexane (1:9) as an eluent to obtain the title compound (2.2 g, 52%) as an orange oil, Rf: 0.36 (1:9 ethyl acetate, hexane); IR (vmax (film)): 2955, 2863, 2842, 1200, 1093, 770 cm-1; 1H NMR (300 MHz, CDCl3): delta 1.24 (9H, s), 1.21-1.42 (2H, m), 1.42-1.58 (2H, m), 1.82-2.02 (1H, m), 3.36 (2H, td, J = 11.8, 2.1 Hz), 3.68 (2H, d, J = 7.2 Hz), 3.89-4.04 (2H, m), 6.06 (1H, s), 6.39 (1H, s), 6.52 (1H, s) ppm; 13C NMR (75 MHz, CDCl3): delta 30.7, 30.9, 32.0, 37.5, 55.8, 67.7, 105.8, 116.2, 120.6, 135.7 ppm; LRMS (-ESI) m/z: 220.4 ([M-H]- 100%)., 101691-65-0

Big data shows that 101691-65-0 is playing an increasingly important role.

Reference£º
Article; Moir, Michael; Boyd, Rochelle; Gunosewoyo, Hendra; Montgomery, Andrew P.; Connor, Mark; Kassiou, Michael; Tetrahedron Letters; vol. 60; 36; (2019);,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

Step 3: Synthesis of Compound B4Prepared as described by adaptation of the following literature reference:Watson, RJ. et al. Tetrahedron Lett. 2002, 43, 683-685.To a solution of 224 g (0.83 mol) of compound B3 in methyl isobutylketone (1.6 L) are added 189 g (1.66 mol) of potassium thioacetate. The beige suspension is stirred at 70 C for 4.5 h. The reaction mixture is cooled to room temperature and water (1.8 L) is added. The organic layer is washed with 10% aqueous K2CO3 solution (1.8 L) and water (1 L). The organic layer is filtered through celite (20 g), activated charcoal (20 g) and Na2S04 (20 g) and the filtrate is concentrated under reduced pressure. The residual oil is azeotroped with methylcyclohexane (200 mL) and n- heptanes (250 mL) to afford 138 g of compound B4 as a yellow-orange oil (CAUTION: Stench.). Yield: 96%; ES-MS: m/z 175 [M+H]; ]H NMR (400 MHz, CHLOROFORM-d) delta ppm 1.23 – 1.40 (2 H, m), 1.59 – 1.78 (3 H, m), 2.33 (3 H, d, 7=4.16 Hz), 2.82 (2 H, dd, 7=6.24, 3.79 Hz), 3.27- 3.39 (2 H, m), 3.88 – 4.02 (2 H, m)

101691-65-0, The synthetic route of 101691-65-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; RIETHER, Doris; ZINDELL, Renee, M.; ERMANN, Monika; WO2011/109324; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

A mixture of sodium hydride (60 wt.% in mineral oil, 15.74 mg) in DMF (0.7 mL) was added to a solution of tert-butyl 2-chloro-5-(5-chloro-2-fluoropyridin-4-yl)phenylcarbamate (213 mg, 0.596 mmol) in DMF (0.70 mL) at 0 C. The resulting mixture was stirred at 0 C for 30 min. To this stirred mixture was then added (tetrahydro-2H-pyran-4-yl)methyl 4- methylbenzenesulfonate (161 mg, 0.596 mmol) in one portion. The mixture was warmed to 40 C and maintained at this temperature for 16 hrs. The reaction mixture was diluted with EtOAc, washed with 1 N aqueous sodium hydroxide solution, water and brine, dried over sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by preparative TLC [silica gel, 1 mm; EtOAc/heptane = 15/85] providing [2-chloro-5- (5-chloro-2-fluoro-pyridin-4-yl)-phenyl]-(tetrahydro-pyran-4-ylmethyl)-carbamic acid tert-butyl ester (176 mg) as a colorless oil. LCMS (m/z): 355.0/356.9 [M+H, loss of t-Bu]; Rt = 1 .21 min., 101691-65-0

As the paragraph descriping shows that 101691-65-0 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; BARSANTI, Paul, A.; HU, Cheng; JIN, Xianming; NG, Simon, C.; PFISTER, Keith, B.; SENDZIK, Martin; SUTTON, James; WO2012/101064; (2012); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics